Open Interest and Volume Dynamics
The open interest (OI) in Aurobindo Pharma’s futures and options contracts rose from 35,065 to 39,765 contracts, an increase of 4,700 contracts or 13.4% on 21 July 2026. This expansion in OI indicates that new positions are being created rather than closed, reflecting fresh interest from market participants. The total volume traded stood at 33,511 contracts, which is slightly lower than the OI, suggesting that while trading activity is robust, it is not excessively speculative.
In monetary terms, the futures segment accounted for approximately ₹51,511 lakhs, while the options segment’s notional value was substantially higher at ₹23,595.97 crores, culminating in a combined derivatives value of ₹54,982 lakhs. This sizeable derivatives turnover underscores the stock’s appeal among institutional and retail traders alike.
Price Performance and Technical Context
Despite the surge in derivatives activity, Aurobindo Pharma’s stock price declined by 2.85% on the day, underperforming its Pharmaceuticals & Biotechnology sector by 1.45% and the broader Sensex by 0.82%. The stock touched an intraday low of ₹1,515, down 4.1% from previous levels, with the weighted average price indicating that most volume traded near this low point. This suggests selling pressure dominated the session.
Technically, the stock remains above its 50-day, 100-day, and 200-day moving averages, signalling a longer-term uptrend. However, it is trading below its 5-day and 20-day moving averages, indicating short-term weakness and a possible trend reversal after two consecutive days of gains. The delivery volume of 3.52 lakh shares fell by 8.53% compared to the five-day average, pointing to reduced investor participation in the cash segment despite active derivatives trading.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Market Positioning and Potential Directional Bets
The increase in open interest alongside a price decline often points to fresh short positions being established, as traders anticipate further downside. However, the sizeable options notional value suggests that some participants may be hedging or speculating on volatility rather than outright directional moves. The mixed signals from moving averages and volume near lows imply a cautious market stance.
Given the stock’s mid-cap status with a market capitalisation of ₹88,749 crores and a Mojo Score of 62.0, the current Mojo Grade has been downgraded from Buy to Hold as of 25 May 2026. This reflects a tempered outlook amid recent volatility and sector headwinds. Investors should note that while the stock remains fundamentally sound within the Pharmaceuticals & Biotechnology sector, short-term technical pressures and derivative market activity warrant close monitoring.
Comparative Sector and Market Context
On 21 July 2026, the Pharmaceuticals & Biotechnology sector declined by 1.44%, with Aurobindo Pharma underperforming this benchmark. The broader Sensex also slipped by 0.82%, indicating a generally cautious market environment. The stock’s liquidity remains adequate, with a trade size capacity of ₹2.38 crores based on 2% of the five-day average traded value, ensuring ease of entry and exit for active traders.
Holding Aurobindo Pharma Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaways and Outlook
For investors and traders, the recent surge in open interest in Aurobindo Pharma’s derivatives signals a shift in market sentiment that could presage increased volatility. The combination of rising OI and falling prices often suggests that bearish bets are gaining traction, although the large options notional value also points to complex strategies involving hedging or volatility plays.
Given the stock’s current Hold rating and mid-cap classification, investors should weigh the short-term technical weakness against the company’s longer-term fundamentals and sector positioning. Monitoring changes in open interest alongside price and volume trends will be crucial to discerning whether the recent activity represents a temporary correction or the start of a more sustained downtrend.
In summary, Aurobindo Pharma’s derivatives market activity reveals an active and evolving landscape of market positioning. While the stock faces short-term headwinds, its established presence in the Pharmaceuticals & Biotechnology sector and solid market cap provide a foundation for recovery should broader market conditions improve.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
